RTW Investments LP lifted its stake in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 41.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,261,496 shares of the company's stock after acquiring an additional 962,834 shares during the period. RTW Investments LP owned 7.35% of ESSA Pharma worth $19,765,000 as of its most recent filing with the Securities & Exchange Commission.
Separately, Parkman Healthcare Partners LLC increased its position in ESSA Pharma by 37.2% during the third quarter. Parkman Healthcare Partners LLC now owns 345,902 shares of the company's stock worth $2,096,000 after purchasing an additional 93,830 shares during the last quarter. Institutional investors and hedge funds own 75.12% of the company's stock.
Analyst Upgrades and Downgrades
EPIX has been the subject of several analyst reports. Jefferies Financial Group cut shares of ESSA Pharma from a "buy" rating to a "hold" rating in a research note on Monday, November 4th. Oppenheimer cut ESSA Pharma from an "outperform" rating to a "market perform" rating in a research note on Monday, November 4th. Finally, Piper Sandler lowered ESSA Pharma from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $15.00 to $2.00 in a research note on Monday, November 4th.
Read Our Latest Stock Report on ESSA Pharma
ESSA Pharma Stock Up 0.3 %
ESSA Pharma stock traded up $0.01 during trading on Thursday, hitting $1.70. The company had a trading volume of 90,410 shares, compared to its average volume of 298,546. The company's 50 day simple moving average is $3.89 and its 200-day simple moving average is $4.94. ESSA Pharma Inc. has a 1-year low of $1.40 and a 1-year high of $11.67.
Insider Activity
In other ESSA Pharma news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of ESSA Pharma stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $1.53, for a total transaction of $12,055,761.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 7,880,971 shares of company stock valued at $12,064,111. 14.70% of the stock is currently owned by company insiders.
ESSA Pharma Profile
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
